Adaptive Biotechnologies (NASDAQ:ADPT) CEO Sells $8,058,805.92 in Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 321,324 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $25.08, for a total value of $8,058,805.92. Following the completion of the sale, the chief executive officer owned 2,180,518 shares of the company’s stock, valued at $54,687,391.44. This trade represents a 12.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Adaptive Biotechnologies Stock Performance

Shares of Adaptive Biotechnologies stock opened at $25.99 on Friday. Adaptive Biotechnologies Corporation has a one year low of $12.00 and a one year high of $26.16. The company has a market cap of $4.15 billion, a price-to-earnings ratio of -63.39 and a beta of 2.08. The company has a debt-to-equity ratio of 2.22, a quick ratio of 4.68 and a current ratio of 4.79. The business’s 50 day moving average price is $22.06 and its 200 day moving average price is $17.35.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative net margin of 20.73% and a negative return on equity of 36.81%. The company had revenue of $71.55 million during the quarter, compared to analysts’ expectations of $65.44 million. During the same quarter in the previous year, the company earned ($0.17) earnings per share. The firm’s quarterly revenue was up 21.5% compared to the same quarter last year. On average, research analysts predict that Adaptive Biotechnologies Corporation will post -0.4 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ADPT shares. Guggenheim lifted their target price on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. TD Cowen lifted their price target on shares of Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. Finally, Morgan Stanley upped their price objective on Adaptive Biotechnologies from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Thursday, July 30th. Five investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus price target of $24.42.

Institutional Investors Weigh In On Adaptive Biotechnologies

Institutional investors and hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies in the 4th quarter valued at about $28,000. Nykredit A S acquired a new stake in shares of Adaptive Biotechnologies during the second quarter worth about $31,000. Allworth Financial LP purchased a new position in shares of Adaptive Biotechnologies in the second quarter valued at approximately $35,000. EverSource Wealth Advisors LLC boosted its stake in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock valued at $38,000 after purchasing an additional 1,565 shares during the period. Finally, KBC Group NV acquired a new position in shares of Adaptive Biotechnologies in the first quarter valued at approximately $45,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.